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ELUCIDATING THE ROLE OF YAP IN DIRECTING MESENCHYMAL STEM 
CELL FATE 
LISA BRENAN 
ABSTRACT 
Mesenchymal stem cells (MSCs) are a type of multipotent stem cell capable of 
differentiating into several cell types, including fat and bone cells.  The Hippo pathway 
effectors TAZ and YAP have been implicated as important regulators of MSC fate, but 
their roles in this process are poorly understood. The goal of my thesis work was to 
illuminate the roles of YAP and TAZ in MSC differentiation. I examined how depleting 
YAP and/or TAZ, or expressing YAP mutants affect the differentiation of C3H10T1/2 
cells, which are a multipotent mouse embryo fibroblast cell line capable of forming bone, 
fat and cartilage. 
Interestingly, knocking down either YAP or TAZ had different effects on 
C3H10T1/2 differentiation. YAP knockdown cells that underwent a brown/beige 
adipogenic protocol showed a significant increase in the amount of lipids produced as 
compared to control, suggesting that YAP has a role in inhibiting adipogenesis in these 
cells. YAP knockdown also increased alkaline phosphatase activity in cells subjected to 
an osteogenic protocol, while simultaneously producing lipid droplets. In contrast, 
knockdown of TAZ resulted in a decrease in both lipogenesis (in adipogenic 
differentiation) and alkaline phosphatase activity (in osteogenic differentiation). These 
observations indicate that depletion of YAP or TAZ leads to defective MSC 
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differentiation, and that without proper YAP and TAZ signaling MSC cells may arrest in 
an immature state.  
Bone Morphogenic Proteins (BMPs) are known to play important roles in MSC 
differentiation, and YAP/TAZ have been implicated in BMP regulation in other systems. 
I therefore hypothesized that YAP/TAZ may affect MSC differentiation in part by 
altering BMP signaling. Analysis of activated phosphorylated Smad1 (p-Smad1), a key 
transcriptional effector of BMP signaling, showed that TAZ and YAP are required to 
promote p-Smad1 levels. Depletion of TAZ and YAP showed an increase in the 
expression of Gremlin1 (GREM1), an inhibitor of BMP signaling, and an increase in the 
expression of BMP4. These observations suggest that TAZ and YAP promote BMP 
signaling by controlling BMP ligand activity. 
Given that BMP signaling has important roles early in MSC differentiation, I 
hypothesized that YAP and TAZ may direct these early processes. To test this, I 
generated dox-inducible C3H10T1/2 cells capable of expressing wild type YAP or two 
mutant forms of YAP: a nuclear localized YAP mutant (YAP-5SA), and a 
transcriptionally inactive YAP mutant (YAP-5SA,S94A). Adipogenic differentiation with 
these cells showed a reduced level of lipogenesis in the constitutively active nuclear YAP 
mutant. Analysis of adipogenic markers by qPCR showed a reduction in both PPARγ and 
UCP1. Osteogenic differentiation experiments in these cells showed that transient 
expression of all forms of YAP increased the amount of alkaline phosphatase activity, 
with the 5SA form showing the greatest activity. RNA expression analysis showed that 
the early marker Runx 2 was highly upregulated in cells overexpressing wild type YAP, 
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while the late markers osteocalcin and osteopontin were greatly reduced in comparison to 
control. As alkaline phosphatase activity is a mid-stage marker for bone differentiation, 
the staining results and qPCR data indicate that overexpression of YAP may result in 
arrest of the differentiation process.  
A microarray was performed using isolates from 10T1/2 cells transduced with 
TAZ, YAP or TAZ/YAP siRNA to further evaluate the mechanism through which TAZ 
and YAP may be acting. The TAZ and YAP double knockdown showed a large change in 
global gene expression as compared to both the control and the single knockdowns. 
Among the genes that showed a large change from control was BMP4, the expression of 
which was reduced more than two-fold over control. Additionally, GREM1 was up-
regulated almost two-fold by the double knockdown. Also upregulated was the gene 
periostin which encodes a protein that enhances BMP incorporation into connective 
tissues, and may play a role in the mineralization of the extracellular matrix of bone. 
Based on my observations, along with those of others, I propose that TAZ and 
YAP are major factors in controlling early cell fate determination of MSCs. There appear 
to be multiple levels of regulation, and thus the next steps should include clarifying the 
roles of YAP and TAZ in vivo, and placing their activity chronologically in the 
differentiation timeline. Such studies will offer insight into stem cell differentiation and 
may eventually allow for therapeutic opportunities.  
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INTRODUCTION 
Stem Cells 
Stem cells are non-specialized cells that are capable of long-term self-renewal as 
well as differentiating into other, more specialized types of cells.  They may be derived 
from embryos (e.g. embryonic stem cells derived from the inner cell mass of an embryo) 
or adult tissues (known as somatic or adult stem cells).  Cells that exhibit stem cell 
properties can be generated by expressing certain genes in somatic cells (known as 
induced pluripotent stem cells or iPSCs).  Stem cells may be totipotent, pluripotent or 
multipotent.  Totipotent stem cells are capable of differentiating into any cell in the 
developing embryo or the extra-embryonic material.  Pluripotent stem cells are able to 
differentiate into any cell in the body, but not extra-embryonic cells.  Multipotent stem 
cells can become cells of several lineages, but do not have the differentiation potential of 
pluripotent cells.   
 Mesenchymal stem cells (MSCs) are a type of multipotent stem cell.  They are 
capable of differentiating into a variety of mesodermal tissues, the best studied of which 
are cells of the bone, fat and cartilage lineages (59).  There is preliminary data indicating 
that MSCs are also able to differentiate into other tissues such as neurons, myocytes and 
endothelial cells, but these results have yet to be confirmed (5).  MSCs were first 
identified in bone marrow, but have since been isolated from a number of tissues (13,74).  
There is evidence that MSCs from different sources have varying differentiation 
potentials (1,29). 
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 MSCs have a fibroblast-like morphology. They were originally identified by A.J. 
Friedenstein and partners from bone marrow isolates as colony-forming-units-fibroblast 
(CFU-F) (20) due to their ability to proliferate into colonies from a single cell.   Other 
studies have identified cell surface markers that are usually present on MSCs and 
determined that they lack most of the markers of hematopoietic cells commonly found 
with them in the bone marrow (9,14,59,65,70).  However, despite a large body of work 
since that time, there is still variation among the criteria that researchers use to determine 
the identity of MSCs in culture.  Additionally, nearly all work done with MSCs has been 
in vitro, due in part to their low abundance in tissues and in part to a lack of cell surface 
markers specific to multipotent MSCs.  This means that the in vivo niche inhabited by 
MSCs is still poorly understood, particularly as MSCs have been isolated from so many 
different tissues where the microenvironments may be quite different.  Still, the 
International Society for Cellular Therapy has proposed three criteria for the positive 
identification of MSCs, which they term “multipotent mesenchymal stromal cells:” 1) 
they must adhere to standard tissue culture plastic in culture, 2) they must express the 
surface markers CD105, CD79 and CD90 but not express hematopoietic markers and 3) 
they must differentiate into osteogenic, adipogenic and chondrogenic cells (14).   
 Other names for MSCs include mesenchymal stromal cells, bone marrow stromal 
cells and osteogenic stem cells and there is some debate as to whether “mesenchymal 
stem cell” is an appropriate name for this group of progenitor cells (5).  The term 
“mesenchymal stem cell” was originally founded on the supposition that MSCs could 
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generate a number of tissues beyond those associated with skeletal lineages.  This 
supposition has yet to be confirmed.   
Mechanotransduction and Stem Cell Differentiation 
 Cells detect and respond to numerous chemical and mechanical signals from both 
within and outside the cell.  The cell is able to integrate these signals from its 
environment and respond accordingly.  Chemical signaling via cellular receptors and 
protein interaction cascades has long been studied in cells, but it is only recently that 
methods of testing mechanical signaling have become available.  Study of the 
transduction of signals from cell-cell or cell-extracellular matrix (ECM) junctions is a 
field still in its infancy, but some of the mechanisms by which cellular 
mechanotransduction takes place are beginning to be understood. 
 The term “mechanotransduction” describes the process of cells converting 
mechanical stimuli from outside the cell to intracellular signals (80).  Mechanosensing 
can be achieved through specialized cellular structures that respond to mechanical stimuli 
with specific biochemical reactions, as is typical of sensory cells, or through a response 
of the protein complexes found at focal adhesions or cellular junctions.  Much of the 
work done on the signaling ability of cells at focal adhesions has looked at the specific 
molecular composition of these complexes.  There have been almost 200 proteins 
identified as components of focal adhesions to date, with approximately half acting as 
binding proteins and the other half acting as regulators of the binding proteins (23).  The 
main component of focal adhesions are integrins, which act as both inside-out and 
outside-in signalers.  Some of the proteins associated with the integrins are signaling 
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molecules which initiate signaling cascades.  These cascades lead to local changes in the 
cytoskeleton and may eventually lead to global changes in the cell, but the cellular 
response may take some time.   
 Cells are able to directly transfer mechanical cues from the cell surface to the 
nucleus via the cellular cytoskeleton (14).  This phenomenon is explained by a cellular 
model called the “tensegrity” model.  The tensegrity model states that a cell, rather than 
being a homogenous “bag” of viscous cytoplasm surrounded by a plasma membrane, has 
a prestiffened cytoskeletal structure, relying mainly on actin and myosin, which connects 
focal adhesions at the plasma membrane to the nuclear lamina by various adapter 
proteins.  Because of the rigid state of the cytoskeleton, mechanical signals received at 
focal adhesions can be transmitted directly to the nucleus far more quickly than is able to 
be achieved by chemical signaling (80). 
 Direct nuclear signaling may be able to effect cellular changes more quickly than 
chemical signaling because the direct contact with the nucleus allows nearly instant 
transduction of signals.  The lamins of the nucleus not only give the nucleus structure, but 
also interact with chromatin and DNA (80), either on their own or through binding to 
other effector proteins.  The result is that transduction of a mechanical signal from the 
plasma membrane to the nucleus could have an immediate effect on chromatin 
modification and transcriptional regulation.  A mechanical tugging on the nuclear lamins 
could also effect changes via the distortion of nuclear pore complexes.  This distortion 
could allow or exclude proteins from the nucleus in a selective manner, providing another 
pathway for signal transduction. Mediating the nucleocytoplasmic shuttling of 
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developmentally important transcriptional regulators is one mechanism by which 
mechanical signals direct cellular processes.  The Myocardin-related transcriptional 
regulators, Serum Response Factor (SRF), YAP/TAZ, β-catenin and SMAD signaling 
molecules have all been implicated in mechanotransduction (68).  Interestingly, these 
transcriptional regulators have important roles in directing stem cell differentiation and 
thus may mediate stem cell activity in response to mechanical signals.  
 Differentiation is the process whereby unspecialized cells become more 
specialized.  This occurs during development as well as in tissue regeneration and wound 
healing.  The end result of this process is a cell dedicated to performing a particular 
function. It is well documented that MSCs are capable of differentiating into cells of the 
osteogenic, adipogenic and chondrogenic lineages.  The possibility of MSCs 
differentiating into other cell types, such as neurons and myocytes, has been suggested 
but not definitively proven.  MSC differentiation can be induced in vitro using either 
chemical or mechanical means.  MSCs plated and grown to confluence can be induced to 
differentiate with specific cocktails of chemicals (7,40,55,89).  For osteogenesis, 
confluent MSCs are incubated with a mix of ascorbic acid, β-glycerophosphate, and 
dexamethasone for 18-21 days.  Adipogenic differentiation is induced with a cocktail of 
dexamethasone, insulin, isobutyl methyl xanthine and indomethacin (9).  Chondrogenesis 
requires centrifugation of the MSCs, followed by culture of the resulting micropellet with 
transforming growth factor β (TGFβ) 1 or 3 and dexamethasone (9,38). 
 Alternatively, many mechanical stimuli have been shown to induce differentiation 
in MSCs (figure 1).  Differences in the stiffness of the matrix that MSCs are plated on 
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can induce them to differentiate, with softer matrices directing cells toward adipogenesis 
(0.7-1kPa), chondrogenesis (~4kPa) or myogenesis (~10kPa) and a harder matrix 
directing cells toward osteogenesis (~40kPa) (18,19,41,97).  The ability of MSCs to 
detect matrix stiffness has been linked to myosin II at focal adhesions (18,69).  Shearing 
forces have also been shown to effect MSC differentiation, with greater force steering 
cells toward bone formation and less force directing them toward fat formation (98).  
More recently, it has been shown that MSC differentiation programs respond as much to 
changes in shearing forces as to the force itself (47,50).  The amount of cell spreading 
and cell shape likewise appears to impact MSC cell fate decisions, with a lesser amount 
of spreading inducing adipogenesis while greater spreading promotes osteogenesis 
(18,21).  The effects of cell shape on MSC differentiation appears to be modulated by 
RhoA, with greater RhoA activity driving osteogenesis and RhoA inhibition leading to 
adipogenesis (53).  Recent evidence also describes a role for the focal adhesion protein 
vinculin as an initiator of mechanotransduction via a MAPK1 binding site that can be 
exposed by stress from the ECM (22,32). 
 
Figure 1: Localization of YAP and TAZ in relation to cell shape and matrix stiffness in mesenchymal 
stem cells.  ECM stiffness can drive localization of YAP and TAZ, which in turn can be a determinant of 
cellular differentiation. 
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 MSCs from diverse sources appear to have varying differentiation potentials.  In 
general, differentiation of tissue-specific stem cells are more effective when 
differentiating toward the tissues from which they originated (60).  The greatest 
adipogenic potential was seen in MSCs derived from adipose tissue, while the greatest 
osteogenic or chondrogenic potential was seen in MSCs derived from bone marrow or 
synovial tissue, respectively. 
The Hippo Pathway 
A prerequisite for the development of multicellularity is the ability to control cell 
proliferation, differentiation and apoptosis.  These processes must be coordinated during 
development and adult tissue maintenance in order to ensure proper functioning of the 
organism.  Dysregulation of these processes lead to a number of diseases, notably 
developmental syndromes and cancer.  
Despite the wide variety of cell types and tissue structures present across the 
animal kingdom, the developmental processes that cultivate these differences are 
controlled by relatively few signaling pathways (58).  These pathways include Hedgehog, 
TGFβ, Wnt, JAK/STAT, RTK, Notch and Hippo. 
The Hippo pathway was originally elucidated in Drosophila melanogaster in 
screens for tumor suppressor genes.  Components of the pathway were identified by 
mosaic screens for tissue overgrowth phenotypes.  The pathway was later characterized 
as a major regulator of organ size in development, with defects in the various pathway 
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constituents resulting in tissue overgrowth due to increased cellular proliferation.  Further 
studies identified the pathway in mammals and confirmed that the pathway is conserved 
in most multicellular organisms.  That the pathway has an important and longstanding 
place in evolutionary history is implied by the identification of pathway constituents in 
some of the earliest multicellular creatures (31) and in the unicellular ancestors of these 
animals (66).   
The Hippo pathway is a highly conserved kinase cascade signaling pathway 
regulated by cell-cell and cell-ECM interactions and cell polarity.  In Drosophila, 
activation of the pathway results in phosphorylation and nuclear export of Yorkie (Yki), a 
transcriptional regulator.  Pathway stimulation occurs when the Ste20 family protein 
kinase Hippo (Hpo) is activated; activated Hpo then phosphorylates the adaptor proteins 
Salvador (Sav) and Mats, which bind to Hpo and the nuclear Dbf-2-related (NDR) family 
protein kinase, Warts (Wts), respectively.  These complexes facilitate the 
phosphorylation and activation of Wts.  Wts is then able to phosphorylate Yki, 
sequestering it in the cytoplasm and preventing its interaction with Scalloped (Sd), a 
transcription factor that requires Yki as a coactivator.  The end result of Hippo pathway 
activation is inhibition of cell proliferation and promotion of apoptosis. 
Upstream activators of the Drosophila Hippo kinase pathway include 
Neurofibromatosis type-2 (NF2)/ Moesin-Ezrin-Rradixin-like protein (Merlin; Mer) and 
Expanded (Ex).  Both are FERM-domain containing adaptor proteins; these domains are 
known in proteins that act as links between transmembrane proteins and the cellular 
cytoskeleton (10).  Investigations into the cellular location of these proteins indicate that 
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they do, indeed, localize to the cell membrane at adherens junctions (6,44).  Another 
protein associated with the Mer/Ex complex is Kidney and Brain Expressed Protein 
(Kibra), also called WW domain-containing protein 1 (WWC1), which appears to 
promote the Mer/Ex interaction.  Interestingly, Kibra has also been reported to interact 
directly with Wts and to be required for phosphorylation of Yki on S168, though it is not 
required for Wts/Yki binding. (24).  A further component of the upstream regulation for 
the Hippo pathway in Drosophila is the protocadherin Fat, which localizes to the apical 
cell membrane, is known to be required for the stability of Ex and may act in parallel to 
Mer (83).  
The core components of the Drosophila Hippo pathway are highly conserved in 
mammals: mammalian sterile 20–like kinase-1 and 2 (Mst1 and Mst2) are redundant 
homologs of Hpo; Salvador homolog 1 (Sav1 or WW45) is the Sav homolog; Mps One 
Binder kinase activator-like 1A and 1B (Mob1A and Mob1B, jointly known as Mob1) are 
homologs of Mats; Large Tumor Suppressor Kinase 1 and 2 (Lats1 and Lats2) are Wts 
homologs; and Yamaguchi 73 and Esh avian sarcoma virus (Yes) – associated protein 
(YAP, also called YAP1) and its paralog Transcriptional Co-activator with PDZ-binding 
motif (TAZ, also known as WW domain-containing transcription regulator 1, referred to 
as WWTR1) are Yki homologs.  The upstream regulators Mer and Kibra are also found 
in mammalian cells.  Several of these mammalian pathway components (Mst2, Mob1, 
Lats1 and YAP) are capable of functionally rescuing the knockout of their homolog in 
Drosophila (17).   
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Hippo pathway regulation in cells is complex.  Cell-contact inhibition of 
proliferation was one of the first activators of the Hippo pathway to be recognized.  This 
is accomplished through the protein components of tight junctions and adherens 
junctions.  Complexes that regulate apicobasal cell polarity, such as the Crumbs (Crb) 
complex, also seem to have an effect on the Hippo pathway (77), as do the dynamics of 
the actin cytoskeleton.  Additionally, Mer and Kibra have been linked to the Hippo 
pathway as upstream effectors, though the exact mechanism remains unclear.  Recently 
identified regulators of the Hippo pathway are G-protein-coupled receptors (GPCRs).  
Various GPCRs have been shown to modulate Hippo signaling (90), with diverse stimuli 
resulting in activation of differing GPCRs that either inhibit or activate the Hippo 
pathway. 
Gene targets of the mammalian Hippo pathway differ from those of the 
Drosophila pathway.  In Drosophila, cycE, diap1 and bantam are well-characterized 
genes that are directly induced by Yki (93).  These genes contribute to the tissue 
overgrowth phenotype by which the pathway was originally identified.  However, in the 
mammalian pathway, cycE is not induced by YAP/TAZ and the diap1 homologs, Bric5 
and Bric2 are only induced depending on the cellular context.  A homolog of bantam has 
not been identified in mammals.  The best characterized gene targets of the mammalian 
Hippo pathway are those whose transcription is controlled by the TEA domain (TEAD) 
family of transcription factors, among them Connective Tissue Growth Factor (CTGF), 
β2 Integrin, Amphiregulin (Areg) and Baculoviral IAP Repeat Containing 5 (Birc5) (52).   
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Drosophila Sd belongs to this family, and in mammals, the transcription factors activated 
are TEADs 1 through 4. 
The mammalian Hippo pathway (figure 2) has largely been characterized in terms 
of its role in cell proliferation and apoptosis.  Mammalian MST1/2 has been shown to be 
activated by Caspase 3 cleavage in response to pro-apoptotic stimuli (26,45,62), with the 
cleaved fragment translocating to the nucleus and phosphorylating histone H2B and 
FOXO3 (46).  The activation of histone H2B results in condensation of the chromatin, 
DNA fragmentation and finally apoptosis.  This cleavage was shown to be a general 
feature of the apoptotic response in many cell types.  Curiously, the Drosophila Hpo 
kinase lacks the Caspase cleavage site identified in MST1, indicating this kinase is an 
unlikely target for Caspases (84).   
The activated Hippo pathway results in the phosphorylation, and thus inactivation 
and cytoplasmic retention, of the Hippo pathway effectors, TAZ and YAP.  When active, 
these effectors act as transcriptional co-activators, binding to transcription factors such as 
the TEAD family and initiating transcription of pro-proliferation genes.  In this way, 
TAZ and YAP promote cell proliferation and direct cells away from apoptosis. 
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Figure 2: The Mammalian Hippo Pathway.  The core pathway is highly conserved and consists of 
MST1/2, LATS1/2 and TAZ/YAP.  Inputs from multiple sources are capable of stimulating the pathway, 
which results in phosphorylation and inhibition of TAZ and YAP. 
In addition to its role in cell proliferation and apoptosis, the Hippo pathway 
appears to crosstalk with many other signaling pathways, including Wnt (2,37,43,76), 
TGFβ/SMAD (77), Notch, Hedgehog (93) and c-Jun N-terminal kinase (JNK) stress-
activated protein kinase (SAPK) (12).  Crosstalk with the Wnt pathway is achieved via 
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the Hippo pathway effector TAZ, which, when phosphorylated, is able to bind to the Wnt 
pathway protein Disheveled (DVL), preventing its phosphorylation and inhibiting the 
downstream activation of the Wnt pathway effector β-catenin, a transcriptional co-
activator for Wnt target genes (76).   
MST2 colocalizes with filamentous actin in the cellular cytoskeleton.  Disruption 
of the actin cytoskeleton causes activation of MST1/2, which subsequently activates the 
JNK SAPK pathway (12), coupling Hippo pathway activation to the dynamics of the 
actin cytoskeleton.  Moreover, Mer, a known upstream regulator of the Hippo pathway, 
has been found to bind to F-actin, which sequesters it from interaction with Wts (88).  In 
turn, this interaction prevents Mer from activating Wts and inhibits the phosphorylation 
of TAZ and YAP.  Mer binding to F-actin may provide another mechanism for relaying 
signals into the cell via the Hippo pathway in response to cytoskeletal alterations.   
A recently described upstream regulator of the Hippo pathway is G-protein-
coupled receptors (GPCRs).  GPCRs are activated by binding of extracellular ligands to 
the receptor, which then relay signals into the cell via their associated G proteins.  It has 
recently been demonstrated that stimulation with serum-borne lysophosphatidic acid 
(LPA) or sphingosine 1-phosphate (S1P) leads to activation of Gα12/13 GTP-binding 
proteins, which then inhibit LATS1/2, instigating nuclear localization of the Hippo 
pathway effectors TAZ and YAP (90).  In contrast, stimulation with the hormones 
glucagon or epinephrine caused an increase in phosphorylation of TAZ and YAP by 
LATS1/2, decreasing their transcriptional coactivator activity (90). 
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Hippo Pathway Effectors: TAZ and YAP 
 YAP and TAZ are homologs of the Drosophila Hippo pathway effector Yki.  
Sudol originally identified YAP in the chicken via its interaction with the Src homology 
domain 3 (SH3) of Yamaguchi 73 and Esh avian sarcoma virus (Yes) (71).  The 
following year, Sudol et al. reported the discovery of YAP in both humans and mice (72).  
It was later reported that humans and mice harbor multiple isoforms of YAP. 
 TAZ was first identified via a screen for 14-3-3 protein binding partners (42).  It 
was characterized as a paralog of YAP that also functioned as a transcriptional co-
activator.  TAZ was also described as binding to a PDZ domain containing protein, 
NHERF-2, that couples plasma membrane proteins to actin in the cytoskeleton, 
implicating a role for TAZ in mechanotransduction. 
 TAZ and YAP share certain structural domains (figure 3), among them a TEAD 
binding site, a transcriptional activation domain (TAD), a PDZ-binding domain at the C-
terminus, a 14-3-3 binding site and WW domains, as well as a coiled coil region.  TAZ is 
the smaller of the two proteins, though both proteins encompass isoforms having either 
one or two WW domains (82).  Additionally, YAP contains a proline rich region at the N-
terminus and an SH3 binding domain that TAZ lacks. 
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Figure 3: The Hippo Pathway Effectors YAP and TAZ.  Homologous transcriptional regulators YAP 
and TAZ share many features, including WW domains, TEAD binding domains, a PDZ-binding site and a 
transcriptional activation domain encompassing the coiled-coil region of the protein.  Additionally, YAP 
has an N-terminal proline-rich region, an SH3 binding site and a PPXΦP motif.  Both proteins contain 
multiple regulatory phosphorylation sites. 
 The various protein binding domains present in TAZ and YAP provide a 
mechanism for regulation of their localization and activity.  The WW domains of TAZ 
and YAP bind to a PPxY (proline/proline/any amino acid/tyrosine) motif; many of the 
proteins containing this PPxY motif are known to be interactors of TAZ and YAP.  In 
addition to the WW domains, TAZ and YAP may be regulated by binding to other 
proteins through the PDZ-binding motif or the 14-3-3 binding site.  PDZ motif-
containing proteins are frequently transmembrane proteins or associated with the 
cytoskeleton.  This motif and the WW domains mediate binding to cell polarity 
complexes such as Crumbs (77), coupling cell density and cell polarity to the Hippo 
pathway. 14-3-3 binding is induced by phosphorylation of TAZ or YAP on Ser89 (in 
human TAZ) or Ser127 (in human YAP) and results in cytoplasmic retention of TAZ and 
YAP.  This phosphorylation is carried out by LATS1/2 through activation of the Hippo 
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pathway; 14-3-3 binding is one of the major regulatory mechanisms for TAZ and YAP.  
Cytoplasmic retention of TAZ and YAP prevents their interaction with nuclear 
transcription factors. 
 LATS1/2 phosphorylates TAZ at four sites (Ser66, Ser89, Ser117 and Ser311) 
and YAP at five sites (Ser61, Ser109, Ser127, Ser164 and Ser397). Ser89 (for TAZ) and 
Ser127 (for YAP) are the most critical of these residues for inhibition and cytoplasmic 
retention (28,95).  LATS1/2 phosphorylation of TAZ and YAP on Ser311 and Ser397, 
respectively, promotes further phosphorylation by CK1ε/δ kinases on Ser300 in TAZ and 
Ser400 or Ser403 in YAP (75).  Modification of the proteins in this way recruits the 
βTrCP/SCF ubiquitin ligase.  This leads to ubiquitination and proteasomal degradation of 
TAZ and YAP (75,93).  TAZ and YAP are also phosphorylated by c-ABL on Tyr321 and 
Tyr 407, respectively.  These modifications result in changed nuclear activity for each: 
YAP phosphorylation by c-ABL in response to DNA damage stabilizes YAP and 
stimulates the expression of proapoptotic genes, whereas c-ABL phosphorylation of TAZ 
in response to hyperosmotic stress results in a physical interaction with nuclear factor of 
activated T cells 5 (NFAT5), and a resultant inhibition of the activity of this transcription 
factor.   
Unshared mechanisms of regulation for TAZ and YAP also exist.  TAZ is 
reported to be phosphorylated on Ser58 and Ser62 by glycogen synthase kinase 3β 
(GSK3β), also targeting TAZ for degradation, while no interaction of GSK3β with YAP 
has been described (36).  Likewise, homeodomain-interacting protein kinase (HIPK2) has 
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been identified as a YAP stabilizer, promoting its nuclear activity (61) while interactions 
with TAZ have not been defined. 
 The TEAD family of transcription factors are major targets of TAZ and YAP.  
They are evolutionarily conserved proteins and orthologs of TEAD transcription factors 
can be found in all eukaryotes, from single-celled organisms to vertebrates.  TEADs play 
a crucial role in development, from early embryonic development to regulation of organ 
size and tissue growth in the later embryo.  They do this through transcription of genes 
that control cell proliferation, cell fate, cell migration and adhesion and apoptosis.  Both 
TAZ and YAP contain a TEAD-binding domain at the N-terminus of the proteins, though 
YAP’s TEAD-binding domain contains a PxxΦP (Φ is a hydrophobic residue) that is 
lacking in the TEAD-binding domain of TAZ.  This lack may be the basis for differential 
activation of TEAD target genes by TAZ and YAP. 
 Aside from the TEADs, numerous other transcription factors have been identified 
as binding partners of TAZ and/or YAP.  They share binding to a few transcription 
factors, including SMAD1/2/3 and RUNX1/2, but they also have binding partners that are 
unique to each of them (52).  YAP binds p63, p73 and EGR1, while binding partners 
unique to TAZ include PPARγ, SMAD4 and PAX3/8.  Additionally, TAZ and YAP are 
able to form dimers with themselves and each other to interact with other transcription 
factors. 
 Though TAZ and YAP have largely been characterized for their roles as 
coactivators, there is evidence that they may also act as transcriptional repressors.  YAP 
may be recruited by RUNX2 to inhibit transcription of osteocalcin (OCN) (91), while 
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TAZ is known to bind to PPARγ to inhibit expression of fatty-acid binding protein αP2 
(FABPαP2) (33). 
 Transcriptionally active TAZ and YAP are nuclear, while the phosphorylated 
proteins are cytoplasmic.  However, there is a role for cytoplasmic TAZ and YAP as 
regulators of other signaling pathways.  An example of this is the aforementioned part 
that phosphorylated TAZ plays in inhibiting the Wnt pathway through interaction with 
DVL.  Phosphorylated TAZ and YAP are also available to interact with the effectors of 
the TGFβ pathway: cytoplasmic YAP acts as a corepressor with SMAD7 to inhibit 
SMAD signaling, while YAP and TAZ binding to SMAD2/3/4 control cytoplasmic 
shuttling of these transcription factors. 
 It has recently been shown that TAZ and YAP regulate expression of secreted 
proteins, indicating a role for Hippo signaling in non-cell autonomous functions (28,92).  
YAP was shown to induce the expression of AREG, leading to the activation of 
epidermal growth factor receptor (EGFR) signaling.  EGFR signaling induces cell 
proliferation and migration.  Interestingly, YAP can also induce expression of negative 
regulators of apoptosis, including BIRC5/surviving and BIRC2/cIAP1, which are 
members of the inhibitor of apoptosis (IAP) family and homologs of the Drosophila 
diap1 gene (15). 
 Cell-contact inhibition was one of the first regulators of TAZ and YAP to be 
identified.   Zhao et al. (95) showed that cell-cell adhesion powerfully restricts TAZ and 
YAP from the cell nucleus.  Cells that express TAZ and YAP mutants that cannot be 
phosphorylated do not respond to cell-cell contacts and continue to proliferate. 
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Establishment of cell polarity is also regulated by cell-cell contacts.  Cellular 
components that control epithelial cell polarity have recently been shown to have 
interactions with Hippo pathway components, including TAZ and YAP.  The Crumbs 
complex of proteins is a major factor in establishing the apical domain of epithelial cells, 
while Scribble establishes the basal-lateral domain.  Members of the Crumbs complex, in 
particular the AMOT family of proteins, have been shown to interact with TAZ and YAP 
and to direct their cellular localization (77).  AMOTL2 inhibits translocation of YAP to 
the nucleus, possibly by stabilizing complexes of MST1/2, LATS1/2 and YAP and 
increasing YAP phosphorylation (81,94).  In contrast, the p130-AMOT isoform is able to 
bind to YAP in the cytoplasm and blocks its phosphorylation by LATS1/2.  Additionally, 
p130-AMOT appears to act as a cofactor with the YAP-TEAD complex in the nucleus, 
helping to regulate a subset of YAP target genes (87).  Scribble appears to inhibit TAZ 
nuclear localization in much the same way that AMOTL2 inhibits YAP (11). 
Along with cell-contact inhibition, more recent evidence linking TAZ and YAP 
localization to changes in the actin cytoskeleton and matrix stiffness indicate a role for 
TAZ and YAP in the transduction of mechanical signals from outside the cell to the cell 
nucleus.  There is some evidence that the signals from GPCRs are transmitted to TAZ 
and YAP via Rho-GTPases (90).  Rho-GTPases are a group of GTPases that effect the 
actin cytoskeleton.  They induce the activation of Rho-kinase (ROCK), which promotes 
nuclear TAZ and YAP. 
Dupont et al. (16) showed that a soft matrix of 0.7 to 1kPa reduced cell spreading 
and promoted cytoplasmic retention of TAZ and YAP, while a stiff 40kPa matrix 
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promoted cell spreading and induced translocation of TAZ and YAP to the nucleus.  
These differences in relation to the stiffness of the ECM influence cell fate decisions in 
mesenchymal stem cells (18), with a stiff matrix and nuclear TAZ and YAP leading to 
osteogenesis and a soft matrix and cytoplasmic TAZ and YAP leading to adipogenesis 
(33).  Chondrogenesis also occurs in response to a softer matrix (approximately 4kPa) 
and cytoplasmic TAZ and YAP (97).  Myogenesis is directed by a slightly firmer matrix 
of approximately 10kPa, though TAZ and YAP localization has not been characterized 
for this line of MSC differentiation.  Interestingly, regulation of localization of TAZ and 
YAP via mechanical cues seems to be independent of the LATS1/2 kinases and the 
canonical Hippo pathway (16). 
 The Hippo pathway and TAZ and YAP have been shown to have important roles 
in embryonic development and stem cell regulation.  It appears that changes in TAZ and 
YAP localization are required for the first cell fate decisions that occur in the blastocyst.  
At the onset of cell compaction and the formation of junctions between cells at the 8-cell 
stage of the embryo, the innermost cells, being more compacted, lose polarity.  This 
change causes a re-localization of TAZ and YAP from the nucleus to the cytoplasm and 
results in differing cell fates, with the outer cells, having nuclear TAZ/YAP, becoming 
the trophectoderm, while the inner cells, with cytoplasmic TAZ/YAP, become the cells of 
the inner cell mass.  TAZ/YAP knockout results in defects of cell fate determination and 
embryonic death prior to implantation (57); however, deletion of either TAZ or YAP 
alone does not show the same phenotype. YAP-null mouse embryos show defects in yolk 
sac vasculogenesis, chorioallantoic fusion, and elongation of the body, resulting in 
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embryonic lethality at day ~8.5 (56).  TAZ-null mice, however, are characterized by renal 
cysts and kidney and lung defects and minor skeletal defects (34,51).  TAZ-null mice 
survive birth, though only about one in five live to adulthood.  Interestingly, YAP 
knockout in the zebrafish (Danio rerio) also results in defects of axis formation and 
elongation and a reduction in the size of the head as well as a delay in key developmental 
events (35). 
 TAZ and YAP also have important roles in stem cells and YAP, in particular, has 
been shown to be highly expressed in mouse embryonic, neural and hematopoietic stem 
cells (63).  Studies have shown that TAZ/YAP activity is required to maintain the 
pluripotent state of stem cells.  Stimulation of the TGFβ pathway activates the 
transcription factors SMAD2/3, which form complexes with TAZ and YAP (77).  These 
complexes bind to TEADs and OCT4 (a core regulator of stem cell pluripotency) to 
maintain the pluripotent state (3).  When the cell receives signals for differentiation, the 
complexes are disassembled with the assistance of the transcription factor Forkhead Box 
H1 (FOXH1) (4).  
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METHODS  
Cell culture and cell sources 
The mouse embryonic fibroblast cell line, C3H/10T1/2 and human embryonic 
kidney 293T (HEK 293T) cells were obtained from American Type Culture Collection. 
Mouse C3H/10T1/2 cell culture 
Mouse C3H/10T1/2 cells were cultured in high-glucose Dulbecco’s Modified 
Eagle Medium (DMEM; Corning CellGro), supplemented with 10% fetal bovine serum 
(FBS; Thermo Scientific) and 1% penicillin/streptomycin (GE Lifesciences) in a 
humidified incubator, in the presence of 5% carbon dioxide (CO2) at 37°C. Aliquots of 
the cells were also cryopreserved in freezing medium by the protocol described below for 
later use. 
Cells were passaged at sub-confluence. To passage, medium was aspirated from 
the tissue culture plates, cells were rinsed once with PBS and were detached from the 
plate via incubation with trypsin (0.25 % trypsin, 1 mM EDTA; GE Lifesciences) for 3 to 
5 minutes at room temperature in the tissue culture hood. Cells were then collected by the 
addition of complete culture medium and passaged. Passage of the cells was performed 
every 2-3 days. 
Cells were counted as described below and plated as described in the 
differentiation protocols. The cell concentration was determined by counting the number 
of cells/1mm2 in a hemacytometer. To improve accuracy, a minimum of 100 cells were 
counted in 3 to 5 1mm2 squares and the number of cells were averaged per 1mm2. This 
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number was then multiplied by 104 to obtain the number of cells/ml of the original 
sample. Finally, the total number of cells was determined by multiplying the number of 
cells/ml with the volume of the medium (in ml) in which cells were resuspended.  
Human embryonic kidney 293T (HEK 293T) cell culture 
The human embryonic kidney 293T (HEK 293T) cell line was used for the 
packaging of the lentiviral vectors listed previously: pLVX-TP-Ctrl (vector with control 
insert), pLVX-TP-3F YAP2A WT (wildtype YAP2A), pLVX-TP-3F YAP2A 5SA 
(constitutively nuclear 5 serine-to-alanine phosphorylation mutant YAP2A), pLVX-TP-
3F YAP2A 5SA/S94A (constitutively nuclear 5 serine-to-alanine phosphorylation mutant 
with mutation in the TEAD-binding domain YAP2A), pLKO1-puro shCtrl (vector with 
control hairpin), pLKO1-puro shTAZ m (mouse TAZ), pLKO1-puro shYAP m67 (mouse 
YAP) (see below for packaging of lentiviruses). 
Cells were grown in high-glucose DMEM (Corning CellGro) supplemented with 
10% FBS (Thermo Fisher), and 1% penicillin/streptomycin (GE Lifesciences) and 
incubated in a humidified incubator at 37°C in the presence of 5% CO2. Cells were 
passaged every 2-3 days. 
Cell cryopreservation and defrosting 
Cells were collected by trypsin treatment as described above and placed in 15ml 
Falcon tubes. They were then centrifuged at 900 rpm for 5 minutes at 4°C. The medium 
was then aspirated and the cell pellet was resuspended in freezing medium consisting of 
culture medium containing 20% FBS (Thermo Fisher) and 10% DMSO (American 
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Bioanalytical. This cell suspension was then aliquoted into cryotubes (Corning 
Bioscience), and stored at -80°C in a styrofoam rack to allow a cooling rate of 1°C per 
minute.  
Cells were thawed rapidly in a waterbath set at 37°C. Immediately after 
defrosting, cells were transferred to a tissue culture plate containing 9.5 ml of pre-
warmed cell culture medium and incubated in a humidified incubator at 37°C in the 
presence of 5% CO2. 
Mouse YAP2A overexpression. 
Plasmids. 
Plasmids used for YAP overexpression in the C3H/10T1/2 cell line were as 
following: pLVX-TP-Ctrl, pLVX-TP-3F YAP2A WT, pLVX-TP-3F YAP2A 5SA, 
pLVX-TP-3F YAP2A 5SA/S94A. 
Mouse TAZ and YAP knockdown. 
Plasmids used for TAZ and YAP knockdown in the C3H/10T1/2 cell line were as 
following: pLKO1-puro shCtrl, pLKO1-puro shTAZ m, pLKO1-puro shYAP m67 
All plasmids were made by previous members of the lab. 
Transformation of plasmids to NEB5α competent cells. 
Transformation of plasmids into NEB5α competent cells (New England Biolabs) 
by heat-shock was performed as follows. 
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Competent cells were removed from the -80°C freezer, placed immediately on 
ice, and allowed to thaw for 2 to 5 minutes. The cells were gently pipetted and 25 μl 
aliquots were placed in chilled microfuge tubes. One microliter of purified plasmid DNA 
of any concentration (20 to 100 ng/μl) was added to the competent cells, gently mixed 
with the tip of the pipette, and incubated on ice for 10 minutes. The tubes where then 
heated to 42°C for 50 seconds in a water bath, and were subsequently placed on ice for 2 
minutes. The full volume of the transformation mixture was then plated on pre-warmed 
(at 37°C) Luria-Bertani (LB) agar plates with appropriate antibiotic selection, and 
incubated overnight at 37°C. The following morning, single colonies were picked and 
inoculated to a starter culture of 5 ml of LB plus the appropriate antibiotic, which was 
incubated for 8 hours at 37°C in a horizontal shaking incubator at 270 rpm.  
Plasmid DNA purification. 
Plasmid purification from transformed cells was performed using the Zymo 
Research ZR Plasmid Miniprep™ - Classic kit (Zymo Research), according to the 
recommendations of the manufacturer. 
After bacterial transformation as described above, the 5ml cultures were 
centrifuged at 3,000 x g for 10 min at 4°C, and the supernatant was aspirated from the 
pellet. The pellet was then resuspended in 200 µl of Buffer P1 by vortexing and moved to 
a microfuge tube. Two hundred microliters of Buffer P2 were then added, mixed 
thoroughly by vigorously inverting the sealed tube 4 to 6 times, and incubated at room 
temperature (RT) for 1-3 min. Then, 400 µl of chilled Buffer P3 were added to the lysate, 
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mixed thoroughly by vigorously inverting 4 to 6 times, and incubated at room 
temperature for 1 min. The tubes were then centrifuged at 15,000 rpm for 3 min. And the 
supernatant removed to a spin column. The spin column was centrifuge at 15,000 rpm for 
30 sec. and the flow through was discarded. The column was washed with 200 µl of 
Endo-wash buffer and spun again at 15,000 rpm for 30 sec. The flow through was again 
discarded and the column washed again with 500 µl of wash buffer. After an additional 
spin at 15,000 rpm for 2 min., the column was removed to a new microfuge tube. One 
hundred microliters of dH2O was added to the column. The column was incubated at 
room temperature for 1 min., then the DNA was eluted from the column by centrifugation 
at 15,000 rpm for 30 sec. The quantity and quality of each plasmid preparation was 
determined using a NanoDrop 2000C spectrophotometer (Thermo Scientific). 
Transfections. 
Transient transfection of mouse C3H/10T1/2 cells for the study of mouse TAZ and 
YAP2A knockdown. 
Mouse C3H/10T1/2 cells were transiently transfected with siRNA using 
Dharmafect 1 Transfection Reagent (GE Lifesciences) according to the recommendations 
of the manufacturer. 
Cells were plated in 6–well plates, containing antibiotic-free medium (2 ml/well), 
at a density of approximately 100,000 cells per well, and allowed to attach. At the time of 
the transfection, the cells were approximately 30 to 50% confluent. For each well, 1 μM 
of siRNA was mixed with 3 µl of Dharmafect reagent, with the mixture diluted to 200 μl 
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total in Opti-mem (Life Technologies), and mixed by pipetting. Samples were incubated 
for 20 min at room temperature and the full 200 µl of the transfection mix was added to 
each well. Cell culture medium was changed after 24 h. 
Lentiviral (LV) production 
HEK293T cells were used to package the lentivirus in order to infect the 
C3H/10T1/2 cells.  
293T cells were plated in 6-well plates at a density of approximately 100,000/well 
in regular cell culture medium composed of high glucose DMEM (Corning CellGro) 
supplemented with 10% FBS (Thermo Scientific) and 1 % of penicillin/streptomycin (GE 
Lifesciences). Cells were allowed to attach and were subsequently transfected with 
TurboFect transfection reagent (GE Lifesciences) according to the recommendations of 
the manufacturer. 
Twenty-four hours post-transfection, the medium in the wells was replaced with 2 
ml of fresh virus medium containing high glucose DMEM (Corning CellGro) 
supplemented with 10% heat-inactivated FBS (Thermo Scientific). Forty-eight hours 
after this media change, the medium containing LV particles was collected. Harvested 
media was filtered through a 0.45 µm syringe filter (EMD Millipore) to remove cell 
debris. Viral supernatant was then aliquoted and stored at -80°C, until needed. Virus was 
made using the previously described plasmids as well as the packaging plasmids ps-
PAX2 and pCMV-VSV-G.  
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Lentiviral (LV) transduction of C3H/10T1/2 cells. 
C3H/10T1/2 cells were transduced with lentiviruses (LVs). First, a TET-ON virus 
was transduced to create a stable cell line with a doxycycline inducible-expression 
cassette, then virus for overexpression of wildtype and mutant forms of mouse YAP2A 
(as described above) was transduced into the stable TET-ON cells. 
Cells were plated in 6-well tissue culture plates (FalconTM Becton Dickinson), at a 
density of 100,000 cells/well, in a medium (2 ml/well) composed of DMEM (Corning 
CellGro) supplemented with 10% FBS (Thermo Scientific) and 1% 
penicillin/streptomycin (GE Lifesciences) and were allowed 2 to 4 h to attach. Aliquots 
of viral supernatants (described previously) were thawed and the entire aliquot was added 
to the well. Twenty-four hours after infection, cells were trypsinized and moved to 10 cm 
dishes (BD Falcon). Forty-eight hours after infection, media was replaced with selection 
media. Selection ran until all cells in a control plate had died. Transduced cells were 
maintained in selection media. Cells were also expanded and frozen down as above for 
stocks. 
Cell differentiation assays 
 Cells used for these experiments had been stably transduced with YAP2A mutant 
overexpressing or TAZ and YAP2A knockdown lentiviruses, or had been transiently 
transduced with TAZ and YAP knockdown lentiviruses or siRNA. 
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In vitro adipogenesis assay of C3H/10T1/2 cells. 
 The in vitro adipogenesis assay with C3H/10T1/2 cells for brown fat 
differentiation was performed as described by McDonald, et. al. 2015(54). Cells were 
collected as for passaging and counted as described above. Cells were then plated at a 
concentration of 1.64 x 105 cells per well in 6-well plates and allowed to attach for 1 
hour. Cells were then treated with BMP7 (Peprotech) at a concentration of 1.25pM for 
three days. Doxycycline-inducible cells were also treated with doxycycline (Clontech) at 
0.5 μg/ml at the same time. After treatment with BMP for 72 h, the medium was changed 
to an adipogenic induction medium, consisting of growth medium supplemented with 5 
μM dexamethasone (Sigma), 52 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma), 5 
μg/ml insulin (Sigma, USA), 2 mM T3 (Sigma) and 12.5 mM indomethacin (Sigma).  
After 24 h, the adipogenic induction medium was replaced with adipogenic 
maintenance medium, consisting of growth medium supplemented with 2.5 μg/ml insulin 
(Sigma, USA) and 2 mM T3 (Sigma). The cells were maintained in this media for a total 
of 7 days, with media being refreshed every 2-3 days. On day 8, cells were harvested for 
RNA, protein and staining. 
In vitro osteogenesis assay of mouse C3H/10T1/2 cells. 
The in vitro osteogenesis assay with C3H/10T1/2 cells was adapted from the 
protocol described by Carroll et al. 2012(8). Cells used for this experiment were 
previously transduced with the plasmids described above. Cells were collected as for 
passaging and counted as described above. Cells were then plated at a concentration of 
1.64 x 105 cells per well in 6-well plates and allowed to attach for 1 hour. Cells were then 
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treated with BMP7 (Peprotech) at a concentration of 1.25pM for three days. Doxycycline 
inducible cells were also treated with doxycycline (Clontech) at 0.5 μg/ml at the same 
time. 
After 72 h of BMP treatment, the media was aspirated from the plates and cells 
were washed one time with PBS, then the osteogeneic differentiation media was added. 
This media consisted of growth medium supplemented with L-ascorbic acid (Sigma) at 
70 ng/ml, β-glycerophosphate (Sigma) at 8 mM and dexamethasone (Sigma) at 10 ng/ml. 
Osteogenic differentiation was allowed to run for 18 days, with media being refreshed 
every 2-3 days. On day 18, cells were harvested for RNA, protein and staining. 
Histological staining. 
Oil red O staining. 
Oil red O staining protocol was adapted from Wu, et. al. 1998(85). Briefly, 
staining was performed to stain intracellular lipid vacuoles following the in vitro 
adipogenesis assay of C3H/10T1/2 cells as described previously. After 8 days of 
differentiation, cells were washed twice with Ca++- and Mg++-free PBS and were fixed 
with 1 % PFA (Electron Microscopy Sciences) in PBS for 30 min at room temperature. 
Fixing solution was removed, plates were washed two times with PBS and incubated with 
Oil red O working solution (preparation described in appendix 1) for 60 min at room 
temperature. Stain solution was removed. Plates were then rinsed three times with PBS, 
then left in PBS for imaging. Images were taken using a Nikon Coolpix 4300 digital 
camera modified for use with a microscope by a Zarf Enterprise LNS-23D/CP4300 
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microscope adapter lens. Above steps were performed in three empty wells of a 6-well 
plate to obtain blanks for quantitation. 
Oil Red O dye extraction and quantitation protocol was adapted from the protocol 
described by Ramirez-Zacarias et al. 1992(64). The PBS was aspirated from the plates 
and the plates were allowed to dry completely. Oil Red O was extracted using 3.6 ml of 
100% isopropanol per well of a 6-well plate and incubated at room temperature for 10 
min. Extractions were stored in microfuge tubes at 4°C. The absorbance was measured at 
500 nm by spectrophotometry (NanoDrop). 
Staining for alkaline phosphatase activity 
 Staining for alkaline phosphatase (ALP) activity was performed using the 
Leukocyte Alkaline Phosphatase kit (Sigma) according to the manufacturer’s 
instructions. Cells were washed twice with diH2O, then fixed for 30 s with fixative 
solution prepared as per the manufacturer’s instructions from the supplied concentrated 
citrate solution. After fixing, cells were again washed for 45 s with diH2O, then were 
incubated with the alkaline phosphatase staining solution prepared from dissolved Fast 
Blue RR Salt and Napthol AS-MX Phosphate Alkaline Solution. Cells were incubated in 
the dark for 30 m in this solution, then washed for 2 m with diH2O. Cells were then 
counter-stained with hematoxylin for 10 m. The final step was washing of the cells in 
diH2O for 3 m. Cells were then imaged using an inverted, phase contrast light microscope 
(Nikon TMS) in conjunction with a digital camera (Nikon Coolpix 4300) fitted with a 
microscope adapter lens (Zarf Enterprise LNS-23D/CP4300). For quantitation of 
staining, 5 fields were imaged at 20x magnification.  
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Protein extraction and Bicinchoninic protein assay (BCA). 
Cells were rinsed twice with PBS and incubated in 1x protein lysis buffer 
(described in appendix 1) for 10 min at 4 ºC. Cells were lysed by pipetting and the lysate 
was transferred to microfuge tubes. Lysate was spun in a refrigerated centrifuge for 10 
min at 15,000 rpm and 4 ºC. The lysate was removed from the cell debris and protein was 
quantified using the Pierce® BCA Protein Assay kit (Thermo Scientific), according to the 
recommendations of the manufacturer. Pierce® BCA Protein Assay Reagent A was 
diluted 1:50 in Pierce® BCA Protein Assay Reagent B. Four hundred microliters per 
sample of this solution was placed in a disposable cuvette (Denville). Twenty microliters 
of sample was added to the cuvette and the mixture was briefly vortexed. Twenty 
microliters of IP wash buffer was used as a blank. The cuvettes were then incubated for 
20 min at 37°C, and the absorbance was measured at 562 nm by spectrophotometry 
(NanoDrop). The protein samples were then normalized to the lowest protein 
concentration to ensure even loading on the gel. 
Western blotting. 
For Western blotting, samples were prepared such that the amount of protein in 
each sample was equal to that in 100 µl of the lowest sample concentration. These 
samples were mixed with 30 µl of 5x sample buffer (see appendix 1), and boiled at 95°C. 
Samples were allowed to cool and then briefly centrifuged to recover evaporated buffer.   
Samples were electrophoresed on either 8% or 10% polyacrylamide gels in 1x 
running buffer (preparation described in appendix 1) at 200 V for 1 h 30 min. Six 
microliters of BLUEStain 3 protein ladder (Gold Biotechnology) were included. 
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Proteins were transferred to nitrocellulose membrane (BioRad) for 1 h 30 min at 
100 V, using a wet method in the presence of transfer buffer (described in appendix 1). 
Membranes were then blocked in TBST (see appendix 1) containing 5% powdered dry 
milk (Lab Scientific, Inc.) or 5% bovine serum albumin (BSA; Fisher Scientific) (for the 
pSMAD1/5 antibody) for 1 h at room temperature (RT) on a benchtop shaker. 
Membranes were incubated with the primary antibody overnight, on a nutator placed at 
4°C. Primary antibody was dissolved in TBST containing either 5% powdered milk or 
BSA. The following day, membranes were washed three times for 10 min each with 
TBST. The membranes were then probed with a secondary antibody, which was 
conjugated to horseradish peroxidase (HRP), for 1 hour at RT. After incubation with the 
secondary antibody, membranes were washed again three times for 10 min each wash 
with TBST.  
The antibody signal was detected by chemiluminescence, using Super Signal ® 
West Dura or Femto (both Thermo Scientific) as a substrate, using a ChemiDox XRS+ 
imager (BioRad) and Image Lab analysis software (BioRad) Version 5.1. 
Gene expression analysis. 
Ribonucleic acid (RNA) extraction. 
RNA from cells in monolayers was extracted with the RNeasy® Mini kit 
(Qiagen) according to the manufacturer’s instructions. Flow through was discarded at 
each step until the final elution. The medium was removed and cells were washed once 
with PBS. Cells were then lysed in 350 µl of Buffer RLT. The cell and buffer RLT 
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mixture was passed 4 to 6 times through a 23 G needle to assist lysis. This lysate was 
then spun in a centrifuge at 15,000 rpm for 3 min to clear cell debris. The supernatant 
was mixed with 350 µl of 70% ethanol (Pharmaco-Aaper) to precipitate RNA. The 
mixture was then placed on a spin column and spun at 15,000 rpm for 15 sec. Cells were 
washed with 700 µl of Buffer RW1, then centrifuged again at 15,000 rpm for 15 sec. The 
column was washed with 500 µl of Buffer RPE. Following another 15 sec spin at 15,000 
rpm, the column was washed a final time with 500 µl of Buffer RPE and spun at 15,000 
rpm for 2 min to dry the column. Finally, RNA was eluted from the column with 30 µl of 
RNase-free water and a 15 sec spin at 15,000 rpm. RNA purity and concentration was 
checked with the NanoDrop 2000C (Thermo Scientific). 
Reverse transcription - complementary deoxyribonucleic acid (cDNA) synthesis. 
For cDNA synthesis, the iScript Reverse Transcriptase kit (BioRad) was used 
according to the manufacturer’s protocol. Briefly, 1 µg of RNA was mixed in 8 strip PCR 
tubes (Fisher Scientific) with 4 µl iScript Reaction Mix and 1 µl iScript Reverse 
Transcriptase, then the final volume was brought to 20 µl with dH2O. Tubes were placed 
in a MyCycler Thermal Cycler (BioRad) set with the following program: 5 min at 25°C, 
30 min at 42°C and 5 mi at 85°C. The cDNA was then allowed to cool, and the volume 
brought to 200 μl by adding 180 μl of dH2O. Samples were stored at -20°C. All samples 
within a single experiment were subjected to cDNA synthesis simultaneously. 
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Quantitative real time polymerase chain reaction (qPCR). 
Quantitative real time polymerase chain reaction (qPCR) was performed in a total 
reaction volume of 10 μl. Each reaction consisted of 5 μl Fast SYBR-green (Applied 
Biosystems), 2 μl (1 μM) each of sense and antisense primers and 1 μl complementary 
deoxyribonucleic acid (cDNA), that was produced as described in section above. 
The primers used for qPCR were designed with NCBI PrimerBlast software and were all 
intron-spanning. Each sample was plated in duplicate in wells of a 96-well plate qPCR 
plate (Life Technologies), which was sealed with clear TempPlate RT Optical Film (USA 
Scientific) to prevent evaporation or contamination. The plate was quick-spun to 
concentrate all reagents in the bottom of each well. qPCR was performed in a ViiA7 
qPCR thermal cycler (Applied Biosystems) with Viia7 Ruo software, and cyclic 
conditions were as follows: a pre-incubation step at 95°C for 20 sec, followed by 40 
cycles of amplification (95°C for 1 sec, 60°C for 20 sec), and a final melt curve cycle of 
95°C for 15 sec, 60°C for 1 min and 95°C for 15 sec. The relative expression ratio was 
calculated using the ΔΔCT method. DNA primers used for Q-RT-PCR are listed in 
Appendix 2. 
Statistical analysis. 
Statistical analysis was performed with Microsoft Excel 2013 using the Analysis 
ToolPak Add-In. Results have been normalized to control. All results are expressed in 
graphs as mean ± standard deviation from repeats.  
 36 
RESULTS 
INTRODUCTION 
TAZ in Mesenchymal Stem Cells 
TAZ is known to inhibit adipogenesis, and this role has been proposed to be 
mediated via interaction and inhibition of the adipogenic master regulator, PPARγ (7); 
however, all investigations to date have studied TAZ in differentiation of white 
adipocytes. TAZ’s role in differentiation of brown or beige adipocytes has not yet been 
clarified. TAZ has also been shown to promote osteoblastic differentiation by binding to 
and activating Runx2, (40,79). Consistent with a role in osteogenesis, overexpression of 
TAZ increases bone density in mice (86).  
YAP in Mesenchymal Stem Cells 
Descriptions of a role for YAP in mesenchymal stem cells have been somewhat 
contradictory. Roles for YAP in the inhibition of osteogenesis in mesenchymal stem cells 
have been described. One group suggested that tyrosine phosphorylation of YAP 
promotes binding to Runx2 on the osteocalcin (OCN) promoter, preventing OCN 
transcription, and consequently inhibition of osteogenesis (91). Another group proposes 
that YAP is required in moderate amounts for adipogenesis, with either overexpression or 
knockdown resulting in inhibited adipocyte differentiation (67). They propose that YAP 
acts downstream of the Sox2 transcription factors in this context (67). However, others 
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have found that inhibition of YAP is required for adipogenesis (89). YAP has also been 
described as being required for the maintenance of “stemness” in stem cells (48,67). 
In addition to the specific binding to transcriptional regulators of differentiation, 
roles have been described for both TAZ and YAP as integrators of other signaling 
pathways that have been shown to impact differentiation (75,78). These pathways include 
Wnt, TGF-β, BMP and ECM signaling. 
 In this chapter, I describe work that was aimed at understanding the roles of YAP 
and TAZ in mesenchymal stem cell differentiation. While I examined both YAP and 
TAZ, the role of TAZ in mesenchymal stem cell differentiation is somewhat better 
understood than that of YAP, and thus many of my experiments focused primarily on 
YAP. 
YAP knockdown in Mesenchymal Stem Cell Differentiation 
 To evaluate the role of YAP in MSC fat differentiation, I performed adipogenic 
differentiations using a protocol that induces the differentiation of C3H10T1/2 cells into 
brown fat cells. C3H10T1/2 cells are a multipotent mouse embryo fibroblast cell line 
capable of forming bone, fat and cartilage, among other tissues (25).   
 C3H10T1/2 cells that had been stably transfected with shRNA targeting YAP or 
TAZ were subjected to brown fat differentiation. The YAP knockdown cells showed a 
significant increase in the amount of lipids produced as compared to control (Figure 4), 
while TAZ knockdown showed a decrease in lipids. The staining results were confirmed 
with qPCR to measure expression of adipogenic marker mRNA (Figure 5). These results 
imply that YAP is inhibiting brown fat differentiation in these cells. 
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Figure 4 Oil Red O staining of intracellular lipids in knockdown cells. A) Western blot for knockdown 
of TAZ and YAP. B) Representative images of Oil Red O staining of lipids in shRNA transduced TAZ and 
YAP knockdown 10T1/2 cells. C) qPCR for mRNA expression of TAZ and YAP. D) Quantification by 
spectrophotometry of Oil Red O staining of cells in A. *P < .05, **P < .01, ***P < .001 
 
Figure 5 Expression of brown adipogenic markers in knockdown cells. Quantification of mRNA 
expression of established brown fat markers in the differentiation of shRNA transduced TAZ and YAP 
knockdown 10T1/2 cells. *P < .05, **P < .01, ***P < .001 
 I also looked at the osteogenic differentiation capacity of the C3H10T1/2 stable 
knockdown cells. Knockdown of TAZ in C3H10T1/2 cells exposed to an osteogenic 
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differentiation protocol reduced the amount of differentiation as assayed by staining for 
alkaline phosphatase activity (figure 6). In contrast, YAP knockdown increased both the 
number of cells expressing alkaline phosphatase and the intensity of the staining. qPCR 
analysis showed no change in the early osteogenic marker, Runx 2, but the YAP 
knockdown showed a large induction of the later marker, osteocalcin (OCN) (figure 7). 
YAP appears to inhibit bone differentiation in C3H10T1/2 cells, though this needs to be 
confirmed as the YAP knockdown was not very strong and this experiment has only been 
performed once. 
 
Figure 6 Staining for alkaline phosphatase activity in knockdown cells. A) Representative images of 
staining for alkaline phosphatase activity in shRNA transduced TAZ and YAP knockdown 10T1/2 cells. B) 
qPCR for mRNA expression of TAZ and YAP. *P < .05, **P < .01, ***P<.001 
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Figure 7 Expression of osteogenic markers in knockdown cells. Quantification of mRNA expression of 
established bone differentiation markers in shRNA transduced TAZ and YAP knockdown 10T1/2 cells.  
 Interestingly, there was also conspicuous formation of lipid droplets in the YAP 
knockdown cells subjected to the bone differentiation protocol. There was little to no 
lipid formation seen in either the control or the TAZ knockdown cells, indicating this 
effect was due to the knockdown of YAP, rather than an issue with the differentiation 
protocol. This effect was also seen in all repeats of the experiment, though the lipid 
formation was only quantitated in one repeat (figure 8). This implies that YAP plays a 
role in determining stem cell fate and that removal of YAP leads to a confusion of 
differentiation signals. 
 
Figure 8 Oil Red O staining of intracellular lipids in knockdown bone differentiation. A) 
Representative images of Oil Red O staining of lipids in shRNA transduced TAZ and YAP knockdown 
10T1/2 cells subjected to bone differentiation. B) Quantification by spectrophotometry of Oil Red O 
staining of cells in A. 
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Bone Morphogenic Protein in Mesenchymal Stem Cell Differentiation 
 Bone Morphogenic Proteins (BMPs) are known to play a role in MSC 
differentiation. Interestingly, BMPs, through activation of SMAD signaling, appear to 
have both pro-adipogenic and pro-osteogenic activities (39) and some studies have shown 
that BMP signaling specifically promotes adipogenesis (73). However, other studies have 
shown that BMP signaling must be modulated for the induction of white fat 
differentiation (27). TAZ and YAP are known to be involved in regulation of BMP 
signaling. 
With this in mind, I hypothesized that observed effects of YAP knockdown in 
MSC differentiation may be due to altered BMP signaling. I performed Western blots to 
determine if there were changes in BMP signaling with TAZ and YAP knockdown. I 
transfected 10T1/2 cells with TAZ and YAP siRNA, then induced the cells with BMP 7. I 
probed for pSMAD1/5 as an indicator of activation of BMP signaling. pSMAD induction 
is greatly reduced in the TAZ/YAP double knockdown, while little difference is seen in 
the single knockdowns (Figure 9). This suggests that TAZ and YAP promote BMP 
signaling through activation of SMADs. 
 
Figure 9 pSMAD changes with YAP knockdown. A) Western blot for pSMAD1/5 in TAZ and YAP 
knockdown. B) qPCR for expression of GREM1 in TAZ and YAP knockdown. *P < .05, **P < .01, ***P < 
.001 
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Knowing that TAZ and YAP knockdown impedes BMP signaling, as shown, I 
hypothesized that TAZ and YAP may inhibit expression of proteins that inhibit BMP. A 
known inhibitor of BMPs is Gremlin (GREM1) (27). I postulated that TAZ and YAP 
were regulating expression of GREM1. This proposition was confirmed with qPCR 
(Figure 9). These two experiments demonstrate that TAZ and YAP are promoting BMP 
signaling by inhibiting expression of GREM1. 
YAP overexpression in Mesenchymal Stem Cell Differentiation 
 BMPs act both early and late in differentiation. Knowing this, I generated stably 
transfected CH310T1/2 cells expressing several forms of YAP (Figure 10). These 
constructs are under the control of a doxycycline-inducible promoter, allowing me to 
control when these YAP forms are expressed.  
 
 
Figure 10 YAP mutants used for overexpression studies. A) Schematic diagrams showing YAP 
wildtype construct and mutated sites in the YAP mutants. B) Western Blot showing inducibility of YAP 
overexpression. 
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During the differentiation process, cells were induced at day -3 with doxycycline 
during BMP induction (figure 11). Induction with doxycycline ran for three days, and 
then both BMP and doxycycline were removed prior to changing to differentiation media 
on day 0. This produced expression of the YAP constructs that peaked on day 0 and was 
substantially reduced by day 3 (figure 12), limiting high expression to the early time 
points of differentiation.  
 
Figure 11 Timeline of C3H10T1/2 differentiation protocol. Cells were plated and induced with 
doxycycline and BMP at day -3. At day 0, doxycycline and BMP were removed and differentiation 
induction media was added. Terminal differentiation was achieved by day 8 for fat and day 18 for bone. 
 
Figure 12 YAP expression decreases after withdrawal of doxycycline. Western blot for Flag-YAP 5SA 
shows expression fading after removal of dox on day 0. 
Adipogenic differentiation was performed with early BMP and doxycycline 
induction as described above. Overexpression of wildtype YAP and the nuclear/TEAD-
binding mutant (5SA/S94A) modestly increased the amount of lipid from control levels 
(Figure 13), while the constitutively active nuclear mutant (5SA) showed reduced levels 
of lipid accumulation. These results were also confirmed with qPCR for adipogenic 
markers (Figure 14). Wildtype YAP and the 5SA/S94A mutant both showed an induction 
of the brown fat marker UCP1, and wildtype also showed increased levels of the general 
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fat marker PPARγ. In contrast, the 5SA mutant showed reductions in these two markers 
and a moderate increase in the brown fat marker PGC1α. These results imply that nuclear 
YAP may inhibit adipogenesis. 
 
Figure 13 Oil Red O staining of intracellular lipids in overexpressing cells. A) Representative images 
of Oil Red O staining of lipids in 10T1/2 cells overexpressing wildtype and mutant forms of YAP. B) 
Quantification by spectrophotometry of Oil Red O staining of cells in A. 
 
Figure 14 Expression of adipogenic markers in overexpressing cells. Quantification of mRNA 
expression of established adipogenic markers in the differentiation of 10T1/2 cells overexpressing wildtype 
and mutant forms of YAP. Also shown are markers that specify brown fat. *P < .05, **P < .01, ***P < .001 
I also performed osteogenic differentiation experiments in these stably transfected 
C3H10T1/2. All forms of YAP appeared to increase the amount of alkaline phosphatase 
activity, a marker for bone differentiation, with the constitutively active 5SA form 
showing the greatest activity (Figure 15). 
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Figure 15 Staining for alkaline phosphatase activity in overexpressing cells. Representative images of 
staining for alkaline phosphatase activity in 10T1/2 cells overexpressing wildtype and mutant forms of 
YAP. 
Additionally, qPCR was run to identify changes in mRNA expression of 
osteogenic markers (Figure 16). The early marker Runx 2 was highly upregulated in cells 
overexpressing wild type YAP, while the late markers osteocalcin and osteopontin were 
greatly reduced in comparison to control. In contrast, Runx 2 expression in the 5SA and 
5SA/S94A mutants was not obviously changed from control. Additionally, osteopontin 
levels in the 5SA/S94A mutant were increased more than two-fold, while the 5SA mutant 
showed a reduction in osteopontin and no change in osteocalcin. Alkaline phosphatase 
activity is a mid-stage marker for bone differentiation. The staining results combined 
with the qPCR data indicate that overexpression of YAP may result in arrest of the 
differentiation process, with mutations in YAP allowing more or less progress through 
the process but still impeding advancement to full differentiation.  
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Figure 16 Expression of osteogenic markers in overexpressing cells. Quantification of mRNA 
expression of established osteogenic markers in the differentiation of 10T1/2 cells overexpressing wildtype 
and mutant forms of YAP.  
 Remarkably, as in the YAP knockdown cells, the YAP overexpression constructs 
also showed lipid accumulation in the bone differentiations (figure 17). The extent of 
lipid accumulation was in fact greater in the YAP overexpression bone differentiations 
than in the YAP knockdown bone differentiations. The nuclear YAP mutant showed the 
greatest amount of lipid accumulation, while the wildtype and nuclear/TEAD-binding 
mutant showed slightly elevated levels. These results taken together imply that nuclear 
YAP is needed early in differentiation for both osteogenesis and brown adipogenesis, but 
signaling of YAP needs to be modified later for correct response to differentiation 
signals. 
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Figure 17 Oil Red O staining of intracellular lipids in YAP overexpression bone differentiation. A) 
Representative images of Oil Red O staining of lipids in YAP wildtype and mutant transduced 10T1/2 cells 
subjected to bone differentiation. B) Quantification by spectrophotometry of Oil Red O staining of cells in 
A. 
Genome-wide Gene Expression in TAZ/YAP knockdown 
 To further evaluate the mechanism through which TAZ and YAP may be acting, a 
microarray was performed using isolates from 10T1/2 cells transduced with TAZ and 
YAP siRNA. While there were some moderate differences in gene expression between 
the single knockdowns and control, the double knockdown showed a large change in 
global gene expression as compared to both the control and the single knockdowns 
(figure 17). These data indicate that there is some redundancy in the roles of TAZ and 
YAP. The homology between the two proteins (figure 3) and the number of shared 
binding partners that have been identified (52) reinforce this idea. 
 Interestingly, BMP 4 expression was reduced more than two-fold over control in 
the double TAZ/YAP knockdown. Additionally, GREM1 was up-regulated almost two-
fold by the double TAZ/YAP knockdown, consistent with our prior observations.  
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Two integrin subunits (β6 and β7) were also downregulated in the double 
knockdown by at least two-fold, as were a number of other genes associated with 
cytoskeletal arrangements in the cell. 
 Among the genes upregulated at least two-fold by the double knockdown were a 
large number of genes associated with apoptosis, including caspases and apoliprotein L 
family members. Notably, also upregulated was the gene periostin. The protein product 
of this gene enhances BMP1 incorporation into connective tissues and may play a role in 
the mineralization of the extracellular matrix of bone. These data demonstrate further 
support for the idea that TAZ and YAP have a function in BMP signaling and MSC 
differentiation. 
 
Figure 18 Heatmap of gene expression for TAZ and YAP knockdown. A heat map from the DNA 
microarray performed using 10T1/2 cells transduced with control, TAZ, YAP or TAZ and YAP siRNA. 
Results for TAZ/YAP double knockdown cells are shown inside the yellow box.   
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DISCUSSION 
 The role of YAP and TAZ in mesenchymal stem cells appears to be complex. 
Contradictory descriptions of its activity in differentiation, particularly in the case of 
YAP, indicate that we have only scratched the surface of the role of this protein in the 
regulation of MSCs. What can be appreciated is that, among their many functions in the 
cell, YAP and its paralog TAZ are molecular switches that impact MSC cell fate. 
 The results from my differentiation experiments suggest that YAP acts as a 
positive regulator of BMP signaling. Knockdown of TAZ and YAP reduced SMAD1 
phosphorylation, indicating that BMP-mediated SMAD activation is inhibited under these 
conditions. Our microarray data suggest that YAP and TAZ promote the expression of 
BMP4, and repress the expression of the BMP inhibitor Gremlin 1 (GREM1). Indeed, our 
qPCR analysis of GREM showed that it is upregulated upon YAP knockdown, and 
further upregulated with YAP/TAZ knockdown. Additionally, other regulators of BMP 
activity, such as periostin, were shown by our microarray to be effected by YAP/TAZ 
knockdown.  
The induction of a brown adipogenic differentiation program in TAZ and YAP 
knockdown cells showed an increase in lipid accumulation in YAP knockdown cells, 
suggesting that the presence of YAP may inhibit fat production in these differentiating 
cells. This is in agreement with published findings. In this case, YAP appears to perform 
a similar function to TAZ, which has been shown to inhibit white fat adipogenesis. That 
the TAZ knockdown showed a decrease in lipid accumulation from control may indicate 
a role for TAZ in promoting brown fat differentiation, or alternatively may suggest 
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inadequate knockdown in the experiments performed. Further experiments are needed for 
clarification.  
Osteogenic differentiation in TAZ knockdown cells showed decreased alkaline 
phosphatase activity, a marker for bone differentiation. This is in agreement with the 
established role of TAZ in promoting osteogenesis. There was low induction of the late 
marker osteocalcin in the TAZ knockdown cells as compared with control, though there 
was also no downregulation of RUNX2. In contrast, the YAP knockdown cells showed a 
marked increase in alkaline phosphatase activity and a large induction of OCN. This is 
also in agreement with an inhibitory role for YAP in osteogenesis by blocking 
transcription of OCN by RUNX2. That the YAP knockdown cells displayed lipid 
accumulation, even when exposed to a bone differentiation protocol, indicate that nuclear 
YAP may be needed early in the differentiation process to make cell fate determinations. 
My YAP overexpression studies indicate that active YAP may inhibit lipogenesis. 
Notably, expression of the YAP nuclear mutant showed a reduction in Oil Red O staining 
and little induction of brown fat-specific genes. In contrast, the wildtype and 
nuclear/TEAD binding mutant showed small increases in staining for lipids. qPCR for 
general and brown fat markers confirmed these findings, showing a reduction in 
expression of PPARγ, the fat differentiation master regulator, as well as a reduction in the 
brown fat marker UCP1 with the 5SA mutant. Interestingly, the 5SA mutant also showed 
upregulation of the brown fat marker PGC1α, which is a coactivator of PPARγ. PGC1α is 
a major regulator of mitochondrial biogenesis. These results imply that YAP may be a 
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factor in mitochondrial biogenesis independent of adipogenesis. This idea needs further 
investigation.  
 YAP and YAP mutants in the overexpression osteogenic differentiations showed 
an increase in alkaline phosphatase activity. The YAP 5SA mutant displayed the greatest 
activity, followed by the 5SA/S94A mutant and the wild type. Surprisingly, wild type 
YAP, which showed the least alkaline phosphatase activity of the overexpressing YAPs, 
showed a more than 4-fold induction of Runx2, an early osteogenic marker, in qPCR 
studies, with little to no induction of the later markers, osteopontin and osteocalcin. The 
two mutant forms of YAP showed minimal changes in Runx 2. Furthermore, the 
5SA/S94A mutant shows a greater than 2-fold induction of the later marker osteopontin. 
It is known that osteopontin appears earlier than osteocalcin in the differentiation of bone 
(49), so it may be that the 5SA/S94A mutant allows differentiation to progress further but 
the process still arrests at a later timepoint. In addition, alkaline phosphatase activity 
occurs earlier in osteogenesis than induction of either osteopontin or osteocalcin, so the 
staining results may simply represent that the cells are progressing to this point and then 
being arrested at some stage just beyond alkaline phosphatase induction. Such 
intermediate differentiation of stem cells has been described by expression of nuclear-
localized YAP in other systems (96). As in the knockdown bone differentiations, 
overexpression of all forms of YAP also showed lipid accumulation, the nuclear YAP 
mutant showing a very large induction of lipids. Because these constructs were only 
expressed in the cells at early timepoints, this is further evidence that YAP’s action in 
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differentiation may be at an early fate-determining step. Additional studies are needed to 
confirm these results and to define a mechanism for YAP’s regulation of osteogenesis. 
The roles for YAP in differentiation may be related to the crosstalk that occurs 
between the Hippo pathway and other signaling pathways. Wnt and BMP signaling both 
have described roles in development and cellular differentiation, and TAZ and YAP are 
known to interact with key effectors of both of these pathways in several cellular 
contexts. In differentiation, Wnt is thought to be pro-osteogenic and anti-adipogenic, 
while BMP has been described as promoting both osteogenic and adipogenic 
differentiation in MSCs (39). Having demonstrated that YAP effects BMP signaling 
during differentiation, follow-up on how YAP-BMP crosstalk affects MSC fate will be of 
interest. Additionally, there is evidence for TAZ and YAP having opposing roles in 
regulation of Wnt signaling, and it may be that their interactions with Wnt in the context 
of MSC differentiation are important for determining cell fate. Investigating the role of 
TAZ and YAP in Wnt regulation during differentiation may prove to be important to our 
understanding of how these decisions are made. 
Based on my observations, YAP appears to be factor involved in defining MSC 
differentiation. It also appears that TAZ and YAP localization may be a major factor in 
the initial cell fate determination of MSCs. A model can be generated based on my 
findings (Figure 18). There appear to be multiple mechanisms and levels of regulation 
and there is evidence for YAP’s action at several different steps. The complexity of 
YAP’s interactions with other molecules in the differentiation pathways means that there 
is a great deal of work still to be done. Confirmation of the above results with repetition 
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of the experiments is the crucial first step.  Other steps include clarifying YAP’s 
interaction partners and placing them chronologically in the differentiation timeline. 
YAP’s behavior in in vivo differentiation is another important line of investigation. An 
additional area that needs further study is the proposition that YAP is a “stemness” gene 
needed to maintain the potentiality and proliferative ability of stem cells. These studies 
can offer promising insight into stem cell differentiation and may eventually allow for 
therapeutic opportunities.  
 
Figure 19 Proposed model for YAP's role in mesenchymal stem cell differentiation.  
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APPENDIX 1 
Reagents and Equipment 
Cell culture reagents and materials 
Product Name  Company Name 
DMEM (with 4.5g/L glucose, L-glutamine 
and sodium pyruvate) 
Corning CellGro 
OPTI-MEM® +GlutaMax (reduced serum)  Life Technologies 
FBS Thermo Scientific 
Trypsin – EDTA [1x, (0.25% Trypsin, 
1mM EDTA-4Na in HBSS without Ca++ 
and Mg++)] 
GE LifeSciences 
Penicillin/Streptomycin (with 10,000 
units/mL penicillin and 10,000μg/mL 
streptomycin) 
GE LifeSciences 
DMSO (dimethyl sulfoxide) American Bioanalytical 
Agarose LE Gold Biotechnology 
Puromyocin InvivoGen 
G418 Gold Biotechnology 
Hydrochloric acid (HCl), 10N American Bioanalytical 
Potassium chloride (KCl) American Bioanalytical 
Sodium phosphate (Na2HPO4) Fisher Scientific 
Potassium phosphate (KH2PO4) American Bioanalytical 
Cryotube (1.8ml)  Corning Bioscience 
48-well multiwell plates  BD FalconTM , Becton Dickinson 
24-well multiwell plates  BD FalconTM , Becton Dickinson 
12-well multiwell plates BD FalconTM , Becton Dickinson 
6-well multiwell plates  BD FalconTM , Becton Dickinson 
Tissue culture dishes (100 x 20 mm) BD FalconTM , Becton Dickinson 
5 ml serological pipette  Fisher Scientific 
10 ml serological pipette Fisher Scientific 
25 ml serological pipette Fisher Scientific 
15 ml Falcon tubes BD FalconTM 
50 ml Falcon tubes BD FalconTM 
0.22 μm syringe filter Fisher Scientific 
0.45 μm syringe filter  EMD Millipore 
Improved Neubauer Brightline 
Hemocytometer 
Hausser Scientific 
C3H10T1/2, mouse embryo fibroblast cell 
line 
American Type Culture Collection 
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HEK293T, human embryonic kidney cell 
line 
American Type Culture Collection 
In vitro cell differentiation assay reagents 
Product Name  Company Name 
Recombinant human bone morphogenic 
protein 7 (BMP-7) 
Peprotech 
L-ascorbic acid  Sigma 
Glycerol 2-phosphate disodium salt 
hydrate (β-glycerophosphate) 
Sigma 
Triiodothyronine (T3) Sigma 
Dexamethasone  Sigma 
3-isobutyl-1-methylxanthine (IBMX) Sigma 
Indomethacin  Sigma 
Insulin Sigma 
Doxycycline Clontech 
TAZ and YAP siRNA Sigma 
Protein assay reagents and materials 
Product Name  Company Name 
Sodium Fluoride (NaF) Fisher Scientific 
Sodium orthovanadate (Na3Vo) Sigma 
Tween® 20 Fisher Scientific 
BLUEStain 3 protein ladder Gold Biotechnology 
Nitrocellulose membrane BioRad 
Protease inhibitor cocktail, 100x Thermo Scientific 
Aprotonin Pierce Biotechnology 
PEPA Pierce Biotechnology 
Sodium dodecyl sulphate (SDS), 20% in 
water 
American Bioanalytical 
DL-dithiothreitol (DTT) Gold Biotechnology 
Glycerol Fisher Scientific 
Triton X-100 American Bioanalytical 
3’,3’’,5’,5’’-
tetrabromophenolsulfophthalein sodium 
salt (Bromophenol Blue) 
Sigma 
Bovine Serum Albumin (BSA) Fisher Scientific 
Acrylamide Fisher Scientific 
Butanol Fisher Scientific 
Ammonium persulfate (APS) Fisher Scientific 
Tetramethylethylenediamine (TEMED) Thermo Fisher 
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Powdered dry milk Lab Scientific, Inc. 
Tris base Fisher Scientific 
Glycine Fisher Scientific 
Methanol Fisher Scientific 
Whatman paper Fisher Scientific 
Pierce® BCA Protein Assay kit Thermo Scientific 
Disposable Cuvette Denville 
Thermo Scientific Pierce® BCA Protein Assay kit components 
Pierce® BCA Protein Assay Reagent A 
Pierce® BCA Protein Assay Reagent B 
Albumin Standard 
Staining reagents 
Product Name  Company Name 
Ethanol Pharmaco-Aaper 
Oil Red O Alfa Aesar 
Isopropanol American Bioanalytical 
Leukocyte Alkaline Phosphatase kit Sigma-Aldrich 
Paraformaldehyde (PFA), 16% Electron Microscopy Sciences 
Sigma-Aldrich Leukocyte Alkaline Phosphatase kit components 
Fast Blue RR Salt capsules 
Mayer’s Hematoxylin Solution 
Citrate Concentrated Solution 
Napthol AS-MX Phosphate Alkaline Solution 
List of antibodies 
Antibody 
Catalog 
Number 
Supplier Dilution 
Rabbit polyclonal antiTAZ/YAP 8418 Cell Signaling 1:1,000 
Rabbit antiFLAG-HRP A8592 Sigma 1:10,000 
Rabbit polyclonal antiphospho-SMAD1/5 13820S Cell Signaling 1:1,000 
Rabbit antiGAPDH G9545 Sigma 1:1,000 
Rabbit antiGREM1 4383 Cell Signaling 1:1,000 
Rabbit antiSMAD (total SMAD) 1649-1 Epitomics 1:1,000 
Donkey antiRabbit – HRP NA934V GE Healthcare 1:1,000 
Includes primary and secondary antibodies used for immunoblotting with optimal 
dilutions. 
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Cell transformation reagents and materials 
Product Name  Company Name 
NEB5α competent cells New England Biolabs 
Polypropylene, round-bottom tubes  Fisher Scientific 
Yeast extract  American Bioanalytical 
Tryptone Fisher Scientific 
Sodium chloride (NaCl) Fisher Scientific 
Sodium hydroxide (NaOH) American Bioanalytical 
Magnesium chloride (MgCl2) Fisher Scientific 
100 x 20 mm cell culture dishes  Fisher Scientific 
LB Agar Remel 
Carbenicillin Gold Biotechnology 
Spectinomyocin Gold Biotechnology 
ZR Plasmid Miniprep™ - Classic kit Zymo Research 
Zymo Research ZR Plasmid Miniprep™ - Classic kit components 
Collection tubes 
Zymo-Spin™ IIN Columns 
Buffer P1 
Buffer P2 
Buffer P3 
Endo-Wash Buffer 
Plasmid Wash Buffer 
DNA Elution Buffer 
Transfection reagents 
Product Name  Company Name 
TurboFect GE Lifesciences 
Dharmafect GE Lifesciences 
qPCR reagents and materials 
Product Name  Company Name 
8 strip PCR tubes Fisher Scientific 
deoxyribonucleotide triphosphates 
(dNTPs) 
American Bioanalytical 
iScript Reverse Transcriptase kit Bio Rad 
qPCR primers Sigma 
96-well qPCR plates Life Technologies 
TempPlate RT Optical Film USA Scientific 
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Fast SYBR-green Applied Biosystems 
RNeasy® Mini kit Qiagen 
Ethylenediaminetetraacetic acid (EDTA) American Bioanalytical 
Qiagen RNeasy® Mini kit components 
RNeasy® Mini Spin columns  
Collection tubes 
Buffer RLT 
Buffer RW1 
Buffer RPE 
RNase-free water 
iScript Reverse Transcriptase kit components 
iScript Reverse Transcriptase 
iScript Reaction Mix, 5x 
Magnesium chloride (MgCl) 
Nuclease-Free Water 
Equipment 
Item 
Inverted, phase contrast light microscope [Nikon TMS] 
Nikon Coolpix 4300 digital camera 
Zarf Enterprise LNS-23D/CP4300 microscope adapter lens for Nikon Coolpix 4300 
digital camera 
Olympus Camedia D-535 Zoom digital camera 
Image J image processing software 
BioRad ChemiDox XRS+ imager and Image Lab software 
Thermo Scientific NanoDrop 2000C spectrophotometer  
BioRad MyCycler Thermal Cycler PCR machine  
Applied Biosystems ViiA7 qPCR cycler and Viia7 Ruo software 
UVP Visi-Blue transilluminator 
Eppendorf Centrifuge 5424 
Eppendorf Centrifuge 5424R 
Thermo Scientific Multi-Purpose Rotator 
Fisher Scientific Nutator 
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Reagents 
Luria – Bertani (LB) medium 
Luria - Bertani (LB) medium was composed of 1% (w/v) tryptone (Fisher 
Scientific), 0.5% (w/v) yeast extract (American Bioanalytical), and 1% NaCl (Fisher 
Scientific). The pH of the solution was adjusted to 7.5 with sodium hydroxide (American 
Bioanalytical). For the preparation of agar plates, 40g LB Agar (Remel) was dissolved in 
1L dH2O. The solution was subsequently autoclaved, and the appropriate antibiotics were 
added for each plasmid, at a concentration of 50 mg/ml. The LB, agar and antibiotic 
solution was poured into 100 x 15 mm dishes (Fisher Scientific) and allowed to set at 
room temperature. LB was stored at room temperature, while agar plates were preserved 
at 4 to 6°C. 
Paraformaldehyde (PFA), 10% 
Twenty milliliters of 16% PFA solution (Electron Microscopy Sciences) was 
diluted in 12 ml of phosphate buffered solution (PBS) and stored at room temperature.  
Phosphate buffered saline (PBS), 10x 
For use in cell culture and staining, PBS was prepared as a 10X concentrated 
stock, which was diluted accordingly. Final dilution was filtered through a 0.2µm bottle-
top filter for use. PBS for cell culture was stored at 4°C, while PBS for staining was 
stored at room temperature. The 10X solution contained the following final 
concentrations: 1.37 M NaCl (Fisher Scientific); 27 mM KCl (American Bioanalytical); 
100 mM Na2HPO4 (Fisher Scientific); and 18 mM KH2PO4 (American Bioanalytical). 
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The pH of the solution was adjusted to 7.4 with concentrated hydrochloric acid 
(American Bioanalytical) and the volume was brought up to 1 L.  
Protein lysis buffer, 10x 
For use in Western blotting, 10x lysis buffer was prepared to the following final 
concentrations: 500 mM Tris-HCl (pH 7.4; Fisher Scientific), 1500 mM NaCl (Fisher 
Scientific), 10 mM EDTA (American Bioanalytical) and 5% Triton X-100 (American 
Bioanalytical).  
For a working solution, buffer was diluted to 1X in distilled water and protease 
inhibitors were added. Working solution was kept on ice and used the same day. 
Transfer buffer (TB), 10x 
Transfer buffer was prepared as a 10x stock and diluted accordingly for use. The 
stock solution was prepared from 30.3 g Tris base (Fisher Scientific), and 144.1 g glycine 
(Fisher Scientific) dissolved in 800 ml of distilled water, and then made up to 1 L. For 
Western blotting, TB was diluted with distilled water and methanol (Fisher Scientific) to 
1X concentration. Final methanol concentration was 20%. 
Tris buffered saline (TBS), 10x 
TBS was prepared as a 10x concentrated stock solution which was diluted for use 
accordingly. In 800 ml of distilled water, 24.2 g of Tris base (Fisher Scientific), and 87.7 
g of NaCl (Fisher Scientific) were dissolved and the final volume was brought up to 1 L. 
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Tris buffered saline – tween (TBST). 
TBST contains Tris-Buffered saline (TBS) (see previous for preparation) and 
0.1% polyoxyethylenesorbitan monolaurate (Tween®-20) (Fisher Scientific). 
Western Blot sample loading buffer, 5x 
Reducing 5x sample buffer was prepared by mixing 20 ml 0.5 M Tris-HCl (pH 
6.8; Fisher Scientific), 3.9 g DL-dithiothreitol (DTT; Gold Biotechnology), and 5 g 
sodium dodecyl sulphate (American Bioanalytical). Subsequently, 25 ml glycerol (Fisher 
Scientific) and 0.025 g Bromophenol blue sodium salt (Sigma) were added to the 
solution. The solution was mixed and the final volume brought to 50 ml with 0.5 M Tris-
HCl (pH 6.8). The solution was then divided into 1 ml aliquots and were stored at -20°C. 
Aliquots were warmed at room temperature prior to use. 
SDS-PAGE gel resolving buffer 
SDS-PAGE gel resolving buffer consisted of 1.5 M Tris base (Fisher Scientific). 
SDS-PAGE gel stacking buffer 
SDS-PAGE gel stacking buffer consisted of 0.5 M Tris base (Fisher Scientific). 
SDS-PAGE running buffer, 10x 
 Running buffer was prepared as a 10x stock and diluted accordingly. For the 
stock, 121.2 g Tris base (Fisher Scientific), 576 g glycine (Fisher Scientific) and 40 g 
sodium dodecyl sulfate (American Bioanalytical) were dissolved in 3.7 L of dH2O. Once 
dissolved, the volume of the buffer was brought to 4 L and stored at room temperature. 
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Tris-Acetic acid- Ethylenediaminetetraacetic acid (TAE), 50x 
TAE was prepared as a 50x stock and diluted accordingly for use. A solution was 
made of 242 g of Tris base (Fisher Scientific) and 600 ml of dH2O. Once the Tris was 
dissolved, 57.1 ml Glacial Acetic Acid (American Bioanalytical) and 18.6 g of EDTA 
(American Bioanalytical) were added to the solution and the volume was brought to 1 L 
with dH2O. Solution was stored at room temperature. 
Immunoprecipitation (IP) Wash Buffer, 1x 
 IP Wash buffer was prepared to the following reagent concentrations: 50 mM Tris 
(pH 7.4; Fisher Scientific), 150 mM NaCl (Fisher Scientific), 1 mM EDTA (American 
Bioanalytical) and 0.1% Triton X-100 (American Bioanalytical). 
Oil Red O Stock Solution 
 Oil red O stock solution was prepared by dissolving 0.5 g of Oil Red O (Alfa 
Aesar, UK) in 100 ml isopropanol (American Bioanalytical). Solution was stirred 
overnight, then filtered through two layers of Whatman paper (Fisher Scientific).  
For a working solution, 6 ml of the stock solution were diluted with 4 ml of 
distilled water, mixed and filtered with a 0.22µm syringe filter. Working solution was 
used immediately. 
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APPENDIX 2 
List of PCR primers 
Quantitative real time polymerase chain reaction (qPCR) primers specific to mouse 
cDNA. 
Gene/ 
Transcript 
Gene bank 
accession number 
PCR 
product 
size (bp) 
Primer sequence (5’-3’) 
TAZ 
NM_001168281 
127 
CAGCCTCTGAATCATGTGAACCTC 
NM_133784 GGCTAGTGGCCACGACTTGCTGGT 
YAP 
NM_009534.3 
106 
AATGTGGACCTTGGCACACT 
NM_001171147.1 ACTCCACGTCCAAGATTTCG 
PPARγ 
NM_011146.3 
134 
TGGTGCCTTCGCTGATGC 
NM_001127330.1 AATGCGAGTGGTCTTCCATC 
Col10a1  NM_009925.4 100 
ATTATCCACTGCTCCTGGGC 
GAAAGGGTATTTGAGGCAGCA 
Col2a1 
NM_001113515.2 
81 
CCGCGGTCCTACGGTG  
NM_031163.3 CCTTATCTTTATACCTCTGCCCAT 
Sox9  NM_011448.4 95 
CCGGCATGAGTGAGGTGC 
AGCTTGCACGTCGGTTTTGG 
Runx2 
NM_001146038.1 
125 
ATCCCCATCCATCCACTCCA  
NM_009820.4 
NM_001145920.1 GCCAGAGGCAGAAGTCAGAG 
UCP1 NM_009463 136 
GCCTGGCAGATATCATCACCT 
CCTTCTGTTTTTGCCAGGGT 
FABP4 NM_024406 112 
TTCCTTCAAACTGGGCGTGG 
TCCATCCCACTTCTGCACCT 
OCN NM_001037939 132 
TTCTGCTCACTCTGCTGACC 
GCCGGAGTCTGTTCACTACC 
OPN NM_001204233 95 
TTGCTTTTGCCTGTTTGGCA 
GATCTGGGTGCAGGCTGTAA 
ALPL NM_001287176 102 
CCGGCTGGAGATGGACAAAT 
CACAAGTAGGCAGTGGCAGT 
PGC1α 
NM_008904  
80 
TGGAGTGACATAGAGTGTGCT 
NM_177113 TCAGAAAGGTCAAGTTCAGGAAGA 
All original primers were designed with NCBI primer blast tool software. Primers for 
UCP1 and PGC1α were kindly donated by members of the Farmer lab. 
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APPENDIX 3 
List of plasmids 
 Plasmid Name Reference 
1 TET-ON (G418) Hiemer, et. al. 2014 (30) 
2 pLVX-TP-Ctrl Hiemer, et. al. 2014 (30) 
3 pLVX-TP-3F YAP2A WT Hiemer, et. al. 2014 (30) 
4 pLVX-TP-3F YAP2A 5SA Hiemer, et. al. 2014 (30) 
5 pLVX-TP-3F YAP2A 5SA/S94A Hiemer, et. al. 2014 (30) 
6 pLKO1-puro shCtrl Hiemer, et. al. 2014 (30) 
7 pLKO1-puro shTAZ m Hiemer, et. al. 2014 (30) 
8 pLKO1-puro shYAP m67 Hiemer, et. al. 2014 (30) 
9 psPAX2 Hiemer, et. al. 2014 (30) 
10 pCMV-VSV-G Hiemer, et. al. 2014 (30) 
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